Tags

Type your tag names separated by a space and hit enter

Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wkly Rep. 2015 Sep 04; 64(34):944-7.MM

Abstract

Two pneumococcal vaccines are currently licensed for use in the United States: the 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co., Inc.]). The Advisory Committee on Immunization Practices (ACIP) currently recommends that a dose of PCV13 be followed by a dose of PPSV23 in all adults aged ≥65 years who have not previously received pneumococcal vaccine and in persons aged ≥2 years who are at high risk for pneumococcal disease because of underlying medical conditions (Table) (1-4). The recommended intervals between PCV13 and PPSV23 given in series differ by age and risk group and the order in which the two vaccines are given (1-4).

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26334788

Citation

Kobayashi, Miwako, et al. "Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee On Immunization Practices (ACIP)." MMWR. Morbidity and Mortality Weekly Report, vol. 64, no. 34, 2015, pp. 944-7.
Kobayashi M, Bennett NM, Gierke R, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944-7.
Kobayashi, M., Bennett, N. M., Gierke, R., Almendares, O., Moore, M. R., Whitney, C. G., & Pilishvili, T. (2015). Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morbidity and Mortality Weekly Report, 64(34), 944-7. https://doi.org/10.15585/mmwr.mm6434a4
Kobayashi M, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee On Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015 Sep 4;64(34):944-7. PubMed PMID: 26334788.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). AU - Kobayashi,Miwako, AU - Bennett,Nancy M, AU - Gierke,Ryan, AU - Almendares,Olivia, AU - Moore,Matthew R, AU - Whitney,Cynthia G, AU - Pilishvili,Tamara, Y1 - 2015/09/04/ PY - 2015/9/4/entrez PY - 2015/9/4/pubmed PY - 2015/12/15/medline SP - 944 EP - 7 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 64 IS - 34 N2 - Two pneumococcal vaccines are currently licensed for use in the United States: the 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co., Inc.]). The Advisory Committee on Immunization Practices (ACIP) currently recommends that a dose of PCV13 be followed by a dose of PPSV23 in all adults aged ≥65 years who have not previously received pneumococcal vaccine and in persons aged ≥2 years who are at high risk for pneumococcal disease because of underlying medical conditions (Table) (1-4). The recommended intervals between PCV13 and PPSV23 given in series differ by age and risk group and the order in which the two vaccines are given (1-4). SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/26334788/full_citation L2 - https://doi.org/10.15585/mmwr.mm6434a4 DB - PRIME DP - Unbound Medicine ER -